Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants
Romel Rosales, Briana L McGovern, Myosotys Rodriguez, Rocío Leiva-Rebollo, Randy Diaz-Tapia, Jared Benjamin, Devendra K. Rai, Rhonda D. Cardin, Annaliesa S. Anderson, Hala Alshammary, Radhika Banu, Keith Farrugia, Ana S. Gonzalez‐Reiche, Alberto Paniz‐Mondolfi, J. Polanco, Emilia Mia Sordillo, Harm van Bakel, Viviana Simon, Adolfo García‐Sastre, Kris M. White
Topics & Concepts
VirologyBiologyIn vivoSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)In vitroMonoclonal antibodyVirusCoronavirus disease 2019 (COVID-19)AntibodyImmunologyMedicineGeneticsDiseaseInfectious disease (medical specialty)PathologySARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies